| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 103.02 |
| Total Income | 108.17 |
| Expenditure | 87.69 |
| PBT | 20.48 |
| Net Profit | 16.43 |
| OPM | 4.83% |
| NPM | 15.19% |
| EPS | 5.04 |
Senores Pharmaceuticals Reports Significant Increase in Financial Performance for 3rd Quarter of FY25
23 Jan 2025 · 23 Jan 2025, 07:30 pm
Summary
Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, announced its unaudited financial results for the 3rd Quarter of FY25 ended 31st December 2024. The company reported a significant increase in its financial performance, with the Consolidated Financial Highlights showing an Income of INR 288 Crs, EBIDTA of INR 74 Crs, and PAT after Ml of INR 41 Crs for the 9MFY25.
Key Highlights
- 1
Senores Pharmaceuticals reported a Y-o-Y growth of 157% in PAT for 9MFY25 and 162% for SMFY25.
- 2
The company's regulated market business revenues grew by approximately 100% on a Y-o-Y basis for 9MFY25.
- 3
Emerging markets business revenues increased by over 10 times on a Y-o-Y basis for 9MFY25.
- 4
The company launched one new product and received ANDA approval for five products in the Regulated Markets business.
- 5
Senores Pharmaceuticals is realigning its go-to-market models to make its Emerging Markets operations more profitable.
Management Comments
Swapnil Shah
Managing Director, Senores Pharmaceuticals Limited
We are pleased to report strong performance for Q3 and 9MFY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our revenue and profitability for 9MFY25 have increased by over 150% year-on-year, and we are optimistic about sustaining this momentum going forward.
Informational and educational content only. Not investment advice.